

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	N/A
Reporting on race, ethnicity, or other socially relevant groupings	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample-size calculations were performed. Sample size for the mutant virus library used to measure the fitness landscapes was chosen to be one million plaque-forming units in order to thoroughly sample the library complexity of 512 unique variants, and replication studies (Supplementary Figure 3) demonstrated this sample size was sufficiently large to avoid stochastic bottlenecks of library variants. Fitness landscapes were computed based on changes in mutant virus genotype frequency. Genotype frequencies were computed with deep sequencing at depths far exceeding the complexity of the libraries (Supplementary Table 1). The sample size for number of replicate simulations was arbitrarily chosen to be 500, which is sufficient to capture a range of stochastic behavior within the simulations (Figure 4b, Supplementary Figure 11, Supplementary Figure 12).
Data exclusions	No data were excluded from the analyses.
Replication	Two independently-generated mutant virus libraries were used. Every experimental condition for the measurement of fitness landscapes was fully repeated in experimental triplicate. There were high levels of reproducibility between virus libraries and between triplicate experiments of each library (Figure 1D, Supplementary Figure 3)
Randomization	Randomization is not relevant to the experimental design because there were no covariates to control for in the experimental design.
Blinding	Blinding was not relevant to the study because there were no aspects of the study design susceptible to subjective bias.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

## Methods

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

n/a	Involvement
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

## Laboratory animals

No animals were used.

Laboratory strains of *Escherichia coli* were used: Bacterial hosts used for evolution and competition experiments were the Lamb ("L-" strain JW3996) and OmpF ("O-" strain JW0912) knockout strains from the Keio collection. The "wild type" *E. coli* K-12 BW25113 (parental strain in the Keio collection) was used unless otherwise stated to titer  $\lambda$  phages by plaque assay. The host strain HWEC106, which contains a mutation in the mutS mismatch repair gene and the pKD46 plasmid containing the arabinose-inducible  $\lambda$  red recombineering machinery, was used to perform mutagenesis and is the strain that we used to maintain the cl26-derived engineered lysogen library.

Speciation replay experiments used strictly lytic phages derived from the  $\lambda$  phage strain cl26. We engineered a lysogenic form of cl26 by replacing the nonfunctional *ci* gene with a temperature-sensitive mutant (to enable heat induction of the lytic pathway) and adding a constitutively expressed chloramphenicol resistance gene for antibiotic selection of lysogens in the bacterial host HWEC106.

## Wild animals

No wild animals were used.

## Reporting on sex

N/A.

## Field-collected samples

N/A.

## Ethics oversight

All work was performed under the UC San Diego Biological Use Agreement to ensure safe and ethical practices.

Note that full information on the approval of the study protocol must also be provided in the manuscript.